Metastasis therapies for renal cancer
(2016) In Current Opinion in Urology 26(6). p.566-572- Abstract
Purpose of review Although novel targeted therapies for metastatic renal cell carcinoma (RCC) are emerging, metastasectomy still remains the only potentially curable intervention and plays an important role both in disease control, cancer-specific survival (CSS) and overall survival (OS). A systematic review was conducted in 2014 by the European Association of Urology RCC guidelines panel to summarize evidence on the subject at hand. The purpose of this review is to update the current evidence base. Recent findings A total of 17-19% of initially nonmetastatic patients with later RCC metastasis are potentially curable. Complete metastasectomy still remains the sole curative option, continues to show improved OS and CSS and is suggested... (More)
Purpose of review Although novel targeted therapies for metastatic renal cell carcinoma (RCC) are emerging, metastasectomy still remains the only potentially curable intervention and plays an important role both in disease control, cancer-specific survival (CSS) and overall survival (OS). A systematic review was conducted in 2014 by the European Association of Urology RCC guidelines panel to summarize evidence on the subject at hand. The purpose of this review is to update the current evidence base. Recent findings A total of 17-19% of initially nonmetastatic patients with later RCC metastasis are potentially curable. Complete metastasectomy still remains the sole curative option, continues to show improved OS and CSS and is suggested to defer time to palliative targeted therapy. Resectability, long time to recurrence, good performance status and oligometastatic disease have better benefit of metastasectomy. Stereotactic radiotherapy remains an excellent option for local tumor control and symptom control in patients with RCC brain and bone metastases. Minimal-invasive options such as thermal ablation are evolving, albeit the evidence base is small. Novel trials are investigating sequencing of metastasectomy and targeted therapy with results pending. Summary Metastasectomy continues to be supported as beneficial for OS, CSS and progression-free survival in patients with good prognostic factors.
(Less)
- author
- Dabestani, Saeed LU ; Marconi, Lorenzo and Bex, Axel
- publishing date
- 2016-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Kidney cancer, Local therapy, Metastasectomy, Metastasis, Renal cell carcinoma
- in
- Current Opinion in Urology
- volume
- 26
- issue
- 6
- pages
- 7 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:84991238100
- pmid:27471993
- ISSN
- 0963-0643
- DOI
- 10.1097/MOU.0000000000000330
- language
- English
- LU publication?
- no
- id
- 4d2ac5fc-7498-45fc-944a-3bb153f433aa
- date added to LUP
- 2016-11-17 14:17:11
- date last changed
- 2024-03-22 11:38:29
@article{4d2ac5fc-7498-45fc-944a-3bb153f433aa,
abstract = {{<p>Purpose of review Although novel targeted therapies for metastatic renal cell carcinoma (RCC) are emerging, metastasectomy still remains the only potentially curable intervention and plays an important role both in disease control, cancer-specific survival (CSS) and overall survival (OS). A systematic review was conducted in 2014 by the European Association of Urology RCC guidelines panel to summarize evidence on the subject at hand. The purpose of this review is to update the current evidence base. Recent findings A total of 17-19% of initially nonmetastatic patients with later RCC metastasis are potentially curable. Complete metastasectomy still remains the sole curative option, continues to show improved OS and CSS and is suggested to defer time to palliative targeted therapy. Resectability, long time to recurrence, good performance status and oligometastatic disease have better benefit of metastasectomy. Stereotactic radiotherapy remains an excellent option for local tumor control and symptom control in patients with RCC brain and bone metastases. Minimal-invasive options such as thermal ablation are evolving, albeit the evidence base is small. Novel trials are investigating sequencing of metastasectomy and targeted therapy with results pending. Summary Metastasectomy continues to be supported as beneficial for OS, CSS and progression-free survival in patients with good prognostic factors.</p>}},
author = {{Dabestani, Saeed and Marconi, Lorenzo and Bex, Axel}},
issn = {{0963-0643}},
keywords = {{Kidney cancer; Local therapy; Metastasectomy; Metastasis; Renal cell carcinoma}},
language = {{eng}},
month = {{10}},
number = {{6}},
pages = {{566--572}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Current Opinion in Urology}},
title = {{Metastasis therapies for renal cancer}},
url = {{http://dx.doi.org/10.1097/MOU.0000000000000330}},
doi = {{10.1097/MOU.0000000000000330}},
volume = {{26}},
year = {{2016}},
}